Original Article
Kidney International (2005) 67, 1654–1658; doi:10.1111/j.1523-1755.2005.00256.x
Endothelial cell dysfunction: The syndrome in making
EDMOND O'RIORDAN, JUN CHEN, SERGEY V BRODSKY, IVA SMIRNOVA, HONG LI and MICHAEL S GOLIGORSKY
Division of Nephrology and Renal Research Institute, Departments of Medicine and Pharmacology, New York Medical College, Valhalla, New York
Correspondence: Michael S. Goligorsky, New York Medical College, BSB, Room C-23, Valhalla, NY 10595. E-mail:michael_goligorsky@nymc.edu
Abstract
Endothelial cell dysfunction: The syndrome in making. Endothelial cell dysfunction is emerging as the ultimate culprit for diverse cardiovascular diseases and cardiovascular complications in patients with chronic renal diseases, yet the definition of this new syndrome, its pathophysiology and therapy remain poorly defined. Here, we summarize some molecular mechanisms leading from hyperhomocysteinemia, elevated asymmetric dimethylarginine (ADMA) and advanced glycation end products (AGEs)-modified proteins to atherogenic endothelial phenotype and offer a model of endothelial dysfunction based on the interconnectedness of diverse functions.
Keywords:
uncoupled eNOS, oxidative stress, vascular wall, atherogenesis
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated
RESEARCH
Kidney International Original Article
Why do we need a statin trial in hemodialysis patients?
Kidney International Original Article


